Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance

Molecular Cancer Therapeutics

Volumn 14, Issue 4, 2015, Pages 994-1003

  Lee, Hannah H ^a   Leake, Brenda F ^a   Teft, Wendy ^b   Tirona, Rommel G ^b   Kim, Richard B ^b   Ho, Richard H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER B; ORGANIC ANION TRANSPORTER D; ORGANIC ANION TRANSPORTER E; ORGANIC ANION TRANSPORTER F; ORGANIC ANION TRANSPORTER POLYPEPTIDE 5A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; SLCO1B1 PROTEIN, HUMAN; SLCO1B2 PROTEIN, MOUSE; SLCO1B3 PROTEIN, HUMAN; TAXOID; TUBULIN MODULATOR;

ALLELE; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MDCK CELL LINE; MOUSE; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORT ASSAY; TRANSPORT KINETICS; VACCINIA VIRUS; VIRUS RECOMBINANT; ANIMAL; DEFICIENCY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; RAT; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; HUMANS; LIVER; MALE; MICE; MICE, KNOCKOUT; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; RATS; SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1; TAXOIDS; TUBULIN MODULATORS;

EID: 84982166281     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0547     Document Type: Article

References (46)

1. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet 2006;45:235-52.
2. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
3. Baker SD, Verweij J, Cusatis GA, vanSchaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 2009;85:155-63.
4. Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 2012;13:1979-88.
5. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18:4433-40.
6. Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 2012;69:1221-7.
7. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009;404: 160-5.
8. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006;79:570-80.
9. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-92.
10. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, et al. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994;48:1528-30.
11. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
12. Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995;15:331-6.
13. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
14. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806.
15. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003;1609:1-18.
16. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012;33:100-8.
17. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38:778-801.
18. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8.
19. Ho RH, Leake BF, Roberts RL, Lee W, Kim RB. Ethnicity-dependent polymorphism in Na+taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 2004;279:7213-22.
20. Blakely RD, Clark JA, Rudnick G, Amara SG. Vaccinia-T7 RNA polymerase expression system: evaluation for the expression cloning of plasma membrane transporters. Anal Biochem 1991;194:302-8.
21. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001;276: 35669-75.
22. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenetics Genomics 2011;21:103-14.
23. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
24. Fahrmayr C, Konig J, Auge D, Mieth M, Munch K, Segrestaa J, et al. Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKIIOATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line. Br J Pharmacol 2013;169:21-33.
25. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161-8.
26. Kopplow K, Letschert K, Konig J, Walter B, Keppler D.Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005;68:1031-8.
27. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem 2002;277:6497-503.
28. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278:G156-64.
29. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, et al. Endogenous drug transporters in in vitro and in vivomodels for the prediction of drug disposition in man. Biochem Pharmacol 2002;64:1569-78.
30. Zaher H, Meyer zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008;74:320-9.
31. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010;120:2942-52.
32. Fischer WJ, Altheimer S, Cattori V, Meier PJ, Dietrich DR, Hagenbuch B. Organic anion transporting polypeptides expressed in liver and brain mediate uptake of microcystin. Toxicol Appl Pharmacol 2005;203:257-63.
33. Sparreboom A, Mathijssen RH. Hepatic uptake transporters and docetaxel disposition in mice-letter. Clin Cancer Res 2014;20:4167.
34. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-64.
35. van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 2010;127:2959-64.
36. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9:738-84.
37. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007;81:265-9.
38. Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, et al. Influence of garlic (Alliumsativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-40.
39. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al. Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet Genomics 2007;17: 647-56.
40. Chung JY, Cho JY, Yu KS, Kim JR,Oh DS, Jung HR, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342-50.
41. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78: 330-41.
42. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005;77:468-78.
43. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, et al. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 2006;80:477-85.
44. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006;62:567-72.
45. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99.
46. Kiyotani K,Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 2008;99:967-72.